Gregory Bensch, MD
Allergy/ Immunology · Stockton, CANPI 1710950589
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,402,409 of the $1,967,068 with a category attached, or 71.3%. 40 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 36.2% of the total.
Across 2,179 payments — averaging $902.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$713K
- Sanofi$449K
- AstraZeneca$365K
- Teva Pharmaceuticals USA, Inc.$122K
- Incyte Corporation$68K
- Optinose US, Inc.$59K
- plus $192K from 34 others
Across 150 payments — averaging $999.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$67K
- Roche Products Limited$31K
- Teva Pharmaceuticals USA, Inc.$30K
- Genentech, Inc.$22K
Across 2 payments — averaging $17,119 each. An ownership or investment interest held by the physician or an immediate family member.
- Consortium Of Independent Immunology Clinics, LLC$34K
What the payments were for
- Consulting fees$273,77314%
- Speaking & faculty fees$1,402,40971%
- Travel & lodging$246,72113%
- Food & beverage$44,0832%
- Education$820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$1,101,012
- AIRSUPRA$226,545
- TEZSPIRE$106,842
- OPZELURA$66,375
- CINQAIR$63,107
- Xhance$57,443
- VTAMA$51,036
- ProAir Digihaler$43,377
- PALFORZIA$27,730
- AYVAKIT$27,347
- AirDuo RespiClick$24,919
- ArmonAir Digihaler$21,452
- TAPINAROF$13,217
- AirDuo Digihaler$7,158
- FASENRA$6,231
- PROAIR$4,660
- BREZTRI$4,552
- QVAR$4,490
- NUCALA$3,267
- XOLAIR$1,500
How this compares
Too few allergy/ immunology providers in Californiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 74 | $275,595 |
| NucalaMepolizumab | 12 | $130,872 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 100 | $89,467 |
| Spiriva RespimatTiotropium Bromide | 99 | $67,030 |
| Dupixent PenDupilumab | 17 | $64,287 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 13 | $62,274 |
| SymbicortBudesonide/Formoterol Fumarate | 126 | $37,048 |
| XhanceFluticasone Propionate | 46 | $34,561 |
| Breo ElliptaFluticasone/Vilanterol | 63 | $27,371 |
| AirsupraAlbuterol Sulfate/Budesonide | 35 | $25,507 |
| BreynaBudesonide/Formoterol Fumarate | 81 | $16,020 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $14,516 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 103 | $12,589 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 52 | $11,672 |
| DuleraMometasone/Formoterol | 31 | $11,147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta | $6,250 | $247,710175 claims |
| AstraZenecaSymbicort, Airsupra, Breztri Aerosphere | $365,354 | $77,071186 claims |
| Boehringer IngelheimSpiriva Respimat | $8,077 | $67,03099 claims |
| Grifols USA, LLCGamunex-C | $107 | $62,27413 claims |
| Optinose US, Inc.Xhance | $58,609 | $34,56146 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $121,886 | $6,02919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy/ immunology providers in Californiaon file to place this against a meaningful peer group, so we don't.
Other allergy/ immunology in Stockton
- George BenschStockton$78K
- Schuman TamSan Francisco$23K
- Cristina PorchcurrenCamarillo$19K
- Steven PragerSalinas$9K
- William CreightonBrawley$8K
- Janet Kershaw-MclennanAtascadero$8K
- Reyneiro CastroPasadena$7K
- Shouling ZhangDowney$3K
- Michael ReidSan Francisco$937
- Alan GreenGlendale$498
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.